The purpose of this study is to test the ability of a new immune modulator, QBKPN, to boost natural immunity to improve health, including reducing respiratory infections. It will also measure the effect of QBKPN on non-respiratory infections, quality of life and overall survival.
The purpose of this project is to engage Indigenous peoples with respiratory conditions to understand their experiences living with respiratory conditions; to explore Indigenous peoples’ healthcare experiences; and to identify promising practices that can improve the treatment experiences and outcomes among Indigenous peoples with respiratory conditions.
The purpose of this study is to determine if Alpha Lipoic Acid (ALA) reduces inflammation and oxidative stress markers in the blood, as well as
improved blood vessel function in patients with moderate to severe obstructive sleep apnea (OSA).
The purpose of this study is to build a tool to support medical decision-making and the integration of a validated clinical-prediction model into routine care for individuals with chronic obstructive pulmonary disease (COPD).
The purpose of this study is to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension
The purpose of this study is determine if a fixed-dose combination of the drugs macitentan and tadalafil is more effective than therapy with macitentan or tadalafil alone to treat pulmonary arterial hypertension.
The purpose of this study is to determine the lung and immune function benefits of stopping vaping for 72 hours in young adults who use e-cigarettes containing nicotine. The study also aims to determine if telling participants of their own personalized changes to their lung and immune function following the 72 hour abstinence period affects their motivation in quitting vaping.
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or International Treatment (SELECT)
The purpose of this study aims to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
The purpose of this study is to explore certain aspects of the blood and brain to determine how a person may recover from COVID-19. In addition, this study will examine how the different aspects of COVID-19 may affect how a person thinks or feels.
This randomized controlled trial will enrol patients with acute severe brain injury who pass a spontaneous breathing trial but have decreased level of consciousness. It will directly compare (1) prompt extubation vs. (2) prompt tracheostomy vs. (3) usual care, with extubation or tracheostomy timed according to physicians' discretion. The primary outcome will be ICU free days (days spent alive and outside an ICU).
People who may be at increased risk of lung cancer due to age and smoking history will be invited to participate in this international study to determine the best way of using computed tomography (CT) of the chest to screen for early lung cancer. Overseas data show that CT screening (screening tests can find diseases early, when they're easier to treat) can reduce deaths from lung cancer and this study will help determine who is most likely benefit from screening.
Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure (ADVENT-HF)
Sleep Apnea (SA) is a disorder that causes pauses in breathing during sleep that expose the heart to oxygen deprivation. It is common in patients with heart failure (HF) where it is associated with increased risk of hospitalizations and death. It is not known however whether treating SA reduces these risks. This study is looking at whether a respiratory device known as Adaptive Servo Ventilation (ASV) can reduce the rate of cardiovascular hospitalizations and death in subjects with HF and SA.
Closed for Recruitment
The purpose of this study is to understand asthmatic patients' knowledge, perceptions and viewpoints about using a telehealth approach to manage their asthma conditions.
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (REBUILD)
The purpose of this study is to assess the safety and efficacy of pulsed inhaled nitric oxide versus placebo in subjects at risk for pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy.
The purpose of this study is to test the safety and efficacy of an inhaled medication (CSJ117) compared with a placebo for improving lung function in patients with inadequate control of moderate to severe asthma.
A Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Allergic Bronchopulmonary Aspergillosis
The purpose of this study is to determine if dupilumab is effective and safe in decreasing episodes of severe breathing difficulties in patients with allergic bronchopulmonary aspergillosis (ABPA).
The purpose of this study is to determine if BC residents receive, understand and implement public health messages related to wildfire smoke exposures, and to better understand the reach of these messages and identify opportunities for future improvement.
The purpose of this study is to understand how patients with asthma and COPD have been affected by the changes to the health care system as a result of the COVID-19 pandemic.
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER (RANGER)
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients